

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau

(43) International Publication Date  
22 August 2024 (22.08.2024)



(10) International Publication Number  
**WO 2024/173835 A3**

(51) International Patent Classification:

C07K 14/47 (2006.01) A61K 48/00 (2006.01)  
C12N 15/86 (2006.01) A61P 27/16 (2006.01)  
C12N 15/63 (2006.01)

NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,  
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,  
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,  
ZA, ZM, ZW.

(21) International Application Number:

PCT/US2024/016218

(22) International Filing Date:

16 February 2024 (16.02.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

|            |                               |    |
|------------|-------------------------------|----|
| 63/485,656 | 17 February 2023 (17.02.2023) | US |
| 63/545,804 | 26 October 2023 (26.10.2023)  | US |
| 63/618,348 | 07 January 2024 (07.01.2024)  | US |
| 63/549,204 | 02 February 2024 (02.02.2024) | US |

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, CV,  
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,  
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,  
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,  
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,  
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,  
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,  
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(71) Applicant: DECIBEL THERAPEUTICS, INC.

[US/US]; 1325 Boylston Street, Suite 500, Boston, MA  
02215 (US).

(88) Date of publication of the international search report:

10 October 2024 (10.10.2024)

(72) Inventors: HU, Qi-Ying; 1325 Boylston Street, Suite

500, Boston, MA 02215 (US). KEIFER, Orion, Paul,  
Jr.; 1325 Boylston Street, Suite 500, Boston, MA 02215  
(US). KOEHLER, Seth; 1325 Boylston Street, Suite 500,  
Boston, MA 02215 (US). LEE, John; 1325 Boylston Street,  
Suite 500, Boston, MA 02215 (US). PALERMO, Adam;  
1325 Boylston Street, Suite 500, Boston, MA 02215 (US).  
PAN, Ning; 1325 Boylston Street, Suite 500, Boston,  
MA 02215 (US). SELLON, Jonathan, B.; 1325 Boylston  
Street, Suite 500, Boston, MA 02215 (US). WHITTON,  
Jonathon; 1325 Boylston Street, Suite 500, Boston, MA  
02215 (US).

(74) Agent: BELLIVEAU, Michael J. et al.; Clark & Elbing

LLP, 101 Federal Street, 15th Floor, Boston, MA 02110  
(US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,  
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,  
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,  
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,  
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,  
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,

(54) Title: METHODS AND COMPOSITIONS FOR ADMINISTERING OTOFERLIN DUAL VECTOR SYSTEMS

(57) Abstract: The disclosure features compositions and methods for the treatment of sensorineural hearing loss and auditory neuropathy, particularly forms of the disease that are associated with a mutation in otoferlin (OTOF), by way of OTOF gene therapy. The disclosure provides a variety of compositions that include a first nucleic acid vector that contains a polynucleotide encoding an N-terminal portion of an OTOF protein (e.g., an OTOF isoform 5 protein) and a second nucleic acid vector that contains a polynucleotide encoding a C-terminal portion of an OTOF protein (e.g., an OTOF isoform 5 protein). These vectors can be used to increase the expression of OTOF in a subject, such as a human subject suffering from sensorineural hearing loss.



WO 2024/173835 A3